...
机译:基于树突式细胞的活性细胞免疫疗法与DCVAC / PCA在原发性前列腺切除术或救出前列腺癌症治疗后患者中患者的DCVAC / PCA试验
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Univ Hosp Motol V Uvalu 84 Prague 15005 5 Czech Republic;
Sotio Prague Czech Republic;
Sotio Prague Czech Republic;
INSERM Cordeliers Res Ctr U1138 Lab Canc Immune Control &
Escape Paris France;
Inst Hematol &
Blood Transfus Prague Czech Republic;
Charles Univ Prague Fac Med 1 Inst Med Biochem Prague Czech Republic;
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Sotio Prague Czech Republic;
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Sotio Prague Czech Republic;
Sotio Prague Czech Republic;
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Charles Univ Prague Fac Med 2 Dept Immunol V Uvalu 84 Prague 15005 5 Czech Republic;
Immunotherapy; Dendritic cell; Biochemically recurrent prostate cancer; PSA doubling time;
机译:基于树突式细胞的活性细胞免疫疗法与DCVAC / PCA在原发性前列腺切除术或救出前列腺癌症治疗后患者中患者的DCVAC / PCA试验
机译:Getug-AFU 22研究中的晚期毒性和生活质量研究:多中心随机期II试验比较放疗+/- 6个月的Degarelix作为可检测PSA后患者的损伤治疗术后前列腺切除术后
机译:PSA倍增时间(PSADT)和PSA速度(PSAV)在前列腺癌根治性前列腺切除术后发起抢救性放疗的决策过程中可能发挥什么作用?
机译:树突状细胞免疫疗法(DCVAC / PCa)联合化学疗法治疗转移性去势抵抗性前列腺癌的I / II期临床试验
机译:一项针对晚期前列腺癌(mCRPC)的男性患者的三期试验(可行)中,自体树突状细胞免疫疗法(DCVAC / PCa)加入多西他赛化疗中